{"id":{"repo_id":"calgary","oai_identifier":"oai:ucalgary.scholaris.ca:11023/2643"},"canonical_url":"https://search.dev.ndltd.org/etd/calgary/oai:ucalgary.scholaris.ca:11023/2643","repository":{"repo_id":"calgary","name":"University of Calgary","base_url":"https://ucalgary.scholaris.ca/server/oai/request"},"display":{"title":"A Meta-Analysis of Hydroxyurea Use for β-thalassemia: Implications for Clinical Practice and Medical Education","abstract":"Chronic blood transfusion remains the most feasible therapeutic option for the majority of patients with severe β-thalassemia. However, it is associated with serious risks and complications. An alternative option is desirable and may prevent some of the problems associated with current therapy. Hydroxyurea (HU), an oral chemotherapeutic drug, is expected to increase hemoglobin, thereby minimizing the burden of blood transfusion and its complications. The objective of this study was to conduct a systematic review and meta-analysis to evaluate the clinical efficacy and safety of HU in patients with severe β-thalassemia. HU appears to be effective, well tolerated and associated with mild and transient adverse events; however, large randomized clinical trials (RCTs) should be done to confirm such findings. Nonetheless, based on the results of the present meta-analysis, it is recommended that current practice guidelines for severe β-thalassemia be appended to include a trial of HU.","abstract_html":"Chronic blood transfusion remains the most feasible therapeutic option for the majority of patients with severe β-thalassemia. However, it is associated with serious risks and complications. An alternative option is desirable and may prevent some of the problems associated with current therapy. Hydroxyurea (HU), an oral chemotherapeutic drug, is expected to increase hemoglobin, thereby minimizing the burden of blood transfusion and its complications. The objective of this study was to conduct a systematic review and meta-analysis to evaluate the clinical efficacy and safety of HU in patients with severe β-thalassemia. HU appears to be effective, well tolerated and associated with mild and transient adverse events; however, large randomized clinical trials (RCTs) should be done to confirm such findings. Nonetheless, based on the results of the present meta-analysis, it is recommended that current practice guidelines for severe β-thalassemia be appended to include a trial of HU.","abstract_has_math":false,"creators":["Algiraigri, Ali"],"institution":"Graduate Studies","degree_name":"Master of Science (MSc)","degree_level":null,"degree_discipline":"Community Health Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Kassam, Aliya"],"committee_chairs":[],"committee_members":["Oddone Paolucci, Elizabeth","Wright, Nicola"],"year":2015,"date_issued":"2015-11-18","date_published":"2015-11-18","updated_at":"2026-07-24T01:30:33Z","subjects":["Education","Medicine and Surgery"],"languages":["eng"],"rights":["University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission."],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["http://dx.doi.org/10.11575/PRISM/24785"],"render_values":[{"text":"http://dx.doi.org/10.11575/PRISM/24785","href":"http://dx.doi.org/10.11575/PRISM/24785","code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/11023/2643","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Kassam, Aliya"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Oddone Paolucci, Elizabeth","Wright, Nicola"]},{"key":"dc:creator","label":"Author","values":["Algiraigri, Ali"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2015-11-18T18:35:32Z"]},{"key":"dc:date.issued","label":"Date","values":["2015-11-18"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Calgary"]},{"key":"dc:type","label":"Dc Type","values":["master thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Community Health Sciences","Medical Education"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MSc)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Calgary"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Education","Medicine and Surgery"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.doi","label":"DOI","values":["http://dx.doi.org/10.11575/PRISM/24785"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11023/2643"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Chronic blood transfusion remains the most feasible therapeutic option for the majority of patients with severe β-thalassemia. However, it is associated with serious risks and complications. An alternative option is desirable and may prevent some of the problems associated with current therapy. Hydroxyurea (HU), an oral chemotherapeutic drug, is expected to increase hemoglobin, thereby minimizing the burden of blood transfusion and its complications. The objective of this study was to conduct a systematic review and meta-analysis to evaluate the clinical efficacy and safety of HU in patients with severe β-thalassemia. HU appears to be effective, well tolerated and associated with mild and transient adverse events; however, large randomized clinical trials (RCTs) should be done to confirm such findings. Nonetheless, based on the results of the present meta-analysis, it is recommended that current practice guidelines for severe β-thalassemia be appended to include a trial of HU."]},{"key":"dc:title","label":"Title","values":["A Meta-Analysis of Hydroxyurea Use for β-thalassemia: Implications for Clinical Practice and Medical Education"]}]}],"canonical_facts":{"dc:contributor.advisor":["Kassam, Aliya"],"dc:contributor.committeemember":["Oddone Paolucci, Elizabeth","Wright, Nicola"],"dc:creator":["Algiraigri, Ali"],"dc:date.accessioned":["2015-11-18T18:35:32Z"],"dc:date.issued":["2015-11-18"],"dc:description.abstract":["Chronic blood transfusion remains the most feasible therapeutic option for the majority of patients with severe β-thalassemia. However, it is associated with serious risks and complications. An alternative option is desirable and may prevent some of the problems associated with current therapy. Hydroxyurea (HU), an oral chemotherapeutic drug, is expected to increase hemoglobin, thereby minimizing the burden of blood transfusion and its complications. The objective of this study was to conduct a systematic review and meta-analysis to evaluate the clinical efficacy and safety of HU in patients with severe β-thalassemia. HU appears to be effective, well tolerated and associated with mild and transient adverse events; however, large randomized clinical trials (RCTs) should be done to confirm such findings. Nonetheless, based on the results of the present meta-analysis, it is recommended that current practice guidelines for severe β-thalassemia be appended to include a trial of HU."],"dc:identifier.doi":["http://dx.doi.org/10.11575/PRISM/24785"],"dc:identifier.uri":["http://hdl.handle.net/11023/2643"],"dc:language.iso":["eng"],"dc:publisher.institution":["University of Calgary"],"dc:rights":["University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission."],"dc:subject":["Education","Medicine and Surgery"],"dc:title":["A Meta-Analysis of Hydroxyurea Use for β-thalassemia: Implications for Clinical Practice and Medical Education"],"dc:type":["master thesis"],"thesis:degree_discipline":["Community Health Sciences","Medical Education"],"thesis:degree_name":["Master of Science (MSc)"],"thesis:institution_name":["University of Calgary"]},"updated_at":"2026-07-24T01:30:33Z"}